ArticleFrontiers in cardiovascular medicine2026
One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04679740 (RMS), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
RMS (Resorbable Magnesium Scaffolds) Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Magmaris is a bioresorbable magnesium scaffold that has shown favorable safety and efficacy in the treatment of de-novo coronary lesions. Aims: To report 1-year outcomes after Magmaris implantation in patients with predominantly complex coronary lesions in the Resorbable Magnesium Scaffold registry (RMS) and to compare them with outcomes from patients with mainly non-complex lesions in the BIOSOLVE-IV registry. Methods: The RMS registry is an ongoing, prospective, national, multicenter registry conducted in Germany. Enrollment took place from November 2020 until May 2023 at Cardiovascular Center Oberallgaeu-Kempten, Bavaria, Germany. Follow-up was performed by phone 12 months after index procedure. We report 1-year outcomes of the first 100 consecutively enrolled patients and provide an unadjusted statistical comparison with 1-year outcomes from the BIOSOLVE-IV registry. Results: RMS patients were older (64.9 ± 8.5 vs. 61.9 ± 10.5 years; Conclusion: Despite a more complex lesion profile in RMS, no statistically significant differences in 1-year clinical outcomes were observed between the two registries. This analysis is hypothesis-generating though not conclusive. Conclusive analysis can only be provided by a randomized controlled trial. Clinical Trial Registration: RMS registry, NCT04679740.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.